Drug name - Edurant

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2023

(6 months from now)

US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

CN101056673A JANSSEN PRODS 4-[[4-[[4-(2-Cyanovinyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidyl]Amino] Benzonitrile Hydrochloride
Jun, 2015

(7 years ago)

CN101816658A JANSSEN PRODS Pyramine Derivatives For Inhibiting Hiv
Aug, 2022

(a month ago)

CN101816658B JANSSEN PRODS Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

CN1541215A JANSSEN PRODS Hiv Inhibiting Pyrimidine Derivatives
Aug, 2022

(a month ago)

CN100509801C JANSSEN PRODS Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

CN101060844A JANSSEN PRODS Composition Of Rt Inhibitor And Nnrti Containing Pyrimidine
Sep, 2024

(1 year, 10 months from now)

CN101068597A JANSSEN PRODS Fumaric Acid Salt Of 4-((4-((4-(2-Cyanovinyl)-2, 6-) Dimethylphenyl Amido)-2- Pyrimidyl) Amido) Benzonitrile
Sep, 2024

(1 year, 10 months from now)

CN101068597B JANSSEN PRODS 4 - ((4 - ((4 - (2) -2, 6 -) Dimethylphenyl Amido) -2 - Pyrimidyl) Amido) Benzonitrile
Sep, 2024

(1 year, 10 months from now)

CN101060844B JANSSEN PRODS Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Sep, 2024

(1 year, 10 months from now)

IN200400265P1 JANSSEN PRODS Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

IN222987B JANSSEN PRODS A Pyrimidine Compound Of Formula (I)
Aug, 2022

(a month ago)

EP1663240A1 JANSSEN PRODS Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Jul, 2020

(2 years ago)

EP1663240B1 JANSSEN PRODS Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Jul, 2020

(2 years ago)

EP1632232A1 JANSSEN PRODS Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile
Feb, 2022

(7 months ago)

EP1632232B1 JANSSEN PRODS Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile
Feb, 2022

(7 months ago)

EP3808743B1 JANSSEN PRODS Hiv Replication Inhibiting Pyrimidines
Aug, 2022

(a month ago)

EP2298761B1 JANSSEN PRODS Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

EP3808743A1 JANSSEN PRODS Hiv Replication Inhibiting Pyrimidines
Aug, 2022

(a month ago)

EP2298761A1 JANSSEN PRODS Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

EP1789139A1 JANSSEN PRODS Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139B1 JANSSEN PRODS Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1419152B1 JANSSEN PRODS Hiv Inhibiting Pyrimidines Derivatives
Nov, 2026

(4 years from now)

EP1419152A1 JANSSEN PRODS Hiv Inhibiting Pyrimidines Derivatives
Nov, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7638522 JANSSEN PRODS Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile Apr, 2023

(6 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.